※苗字と名前の間にスペースをあけ、入力してください

KATO Kazunori

Faculty
Department of Biomedical Engineering
Research Center for Biomedical Engineering
Research Institute of Industrial Technology
Bio-Nano Electronics Research Centre
Course of Biomedical Engineering
PositionProfessor
Mail
HomepageURL
Birthday
Last Updated :2017/12/19

Researcher Profile and Settings

Education

  •  - 1987 , Tohoku University
  •  - 1991 , Tohoku University
  •  - 1985 , Tohoku University

Degree

  • Ph.D.
  • Master of Pharmacy

Association Memberships

  • American Society of Cancer Research
  • Japanese Society of Gene Therapy
  • Japanese Society of Immunology
  • Japanese Society of Cancer Research

Research Activities

Research Areas

  • Basic medicine, Immunology
  • Boundary medicine, Laboratory medicine
  • Clinical internal medicine, Collagenous pathology/Allergology/Infectious disease medicine
  • Clinical internal medicine, Hematology
  • Clinical surgery, Obstetrics and gynecology
  • Clinical surgery, Urology

Research Interests

    CD48, CD2, CD58, Ly-9

Misc

  • A Novel Screening Method to Establish Tumor-targeting Antibodies Reliable for Drug Delivery System, 133, (9) 931 - 938,   2013
  • A Novel Screening Method to Establish Tumor-targeting Antibodies Reliable for Drug Delivery System, Kato Kazunori, YAKUGAKU ZASSHI, 133, (9) 931 - 938,   2013 ,   Establishment of a system that allows selective drug delivery and gene silencing to a tumor is expected to enable targeted therapy. We constructed a genetically modified adenovirus incorporating an IgG Fc-binding motif from the Staphylococcus protein A, Z33 (Adv-FZ33). By cross-linking the Adv-FZ33 virus and the surface antigen molecules with the targeting monoclonal antibodies (mAbs), we attained highly enhanced gene deliveries into the respective antigen-positive cancer cells. Therefore, we aimed to establish a systematic screening method to search for antibody and cell surface target candidates that would provide highly selective anti-cancer reagents to malignant tumors. Using an Adv-FZ33, hybridoma libraries producing a variety of mAbs for human pancreatic, prostate, lung or ovarian carcinoma cells were screened, and we were able to selectively obtain several mAbs which had potent high affinity and recognized antigens of high structure. Within these mAbs, we have identified tumor cell target molecules including not only carcinoembryonic antigen (CEA), epithelial cell adhesion molecule (EpCAM), epidermal growth factor receptor (EGFR), prostate specific membrane antigen (PSMA) but also novel tumor surface target molecules such as phosphatidic acid phosphatase type 2a (PAP2a) and interleukin-13 receptor variant α2 (IL-13Rα2) as tumor antigens. Overall, these results indicate that this type of inductive method approach is a reliable strategy for screening in antibody therapy on par with antibody-dependent drug-delivery system.
  • Selective gene delivery into target cells by fiber-modified adenovirus, KATO Kazunori, HAMADA Hirofumi, Drug Delivery System, 22, (6) 628 - 635,   2007 11 10 , We focused on the function of fiber-modified adenovirus (Adv-FZ33) that contains a synthetic 33-amino acid derived from protein A. We established the comprehensive procedure for screening antibodies that increase transduction efficiency by binding Adv-FZ33 with various human cancers.
  • VLA-5 Mediated Interaction with Fibronectin Induces Cytokine Production by Human Chondrocytes, YONEZAWA I., 70,   1996 08 25
  • Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo., Mol Ther, 10,   2004
  • Pulmonary surfactant protein A augments the phagocytosis of Streptococcus pneumoniae by alveolar macrophages through a casein kinase 2-dependent increase of cell surface localization of scavenger receptor A., J Biol Chem, 279, (20) 21421 - 21430,   2004
  • BDNF gene-modified mesenchymal stem cells promote functional recovery and reduce infarct size in the rat middle cerebral artery occlusion model., Mol Ther, 9,   2004
  • Myocardial injection of CA promoter-based plasmid mediates efficient transgene expression in rat heart., J Gene Med, 5,   2003
  • Telomerized human multipotent mesenchymal cells can differentiate into hematopoietic and cobblestone area-supporting cells., Exp Hematol, 31,   2003
  • The soluble CD40 ligand sCD154 in systemic lupus erythematosus., J Clin Invest, 104,   1999
  • Mesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model., Mol Ther, 11,   2005
  • Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells., J Clin Invest, 101,   1998
  • Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma., Clin Cancer Res, 8,   2002
  • Natural killer cells attack tumor cells expressing high levels of sialyl Lewis x oligosaccharides., Proc Natl Acad Sci U S A, 99, (21) 13789 - 13794,   2002
  • Local production of the p40 subunit of interleukin 12 suppresses T-helper 1-mediated immune responses and prevents allogeneic myoblast rejection., Proc Natl Acad Sci U S A, 93, (17) 9085 - 9089,   1996
  • T-cell-conditioned medium efficiently induces the maturation and function of human dendritic cells., J Leukoc Biol, 70,   2001
  • Immunoregulation by B7 and IL-12 gene transfer., Leukemia, 11,   1997
  • Cytokines production of U5A2-13-positive T cells by stimulation with glycolipid alpha-galactosylceramide., Eur J Immunol, 30, (8) 2138 - 2146,   2000
  • Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer., Cancer Res, 61,   2001
  • Gene therapy of chronic lymphocytic leukemia., Cancer Res Ther Cont, 7,   1998

Research Grants & Projects

  • Research and development of low-invasive and high-sensitive detection system for novel tumor markers by super-targeting monoclonal antibody, Ministry of Education, Culture, Sports, Science and Technology, Grants-in-Aid for Scientific Research(基盤研究(B)), Kazunori KATO
  • Analysis of interaction of CD40 and CD40-ligand in autoimmune diseases and research for regulation drugs., Ministry of Education, Culture, Sports, Science and Technology, Grants-in-Aid for Scientific Research(基盤研究(B)), Kazunori KATO, The expression of CD154(CD40-ligand) on activated CD4-positive T cells is known to be transient and tightly regulated for antigen-specific immune responses, and is increase, and prolonged among patients with systemic lupus erythematosus(SLE). We investigated the regulation of CD154 expression by determining the protein and mRNA expression with PMA and ionomycin stimulation in CD4-positive T cells, and confirmed their increase and prolongation in SLE T cells. Treatment with actinomycin D, a transcription inhibitor, after PMA and ionomycin stimulation was performed, and the findings revealed that the stability of CD154 mRNA increased significantly in activated SLE T cells compared with that of controls. However, alternations or abnormal sequences were not identified in the 3' untranslated region(3'UTR), including AU-rich elements and CU-rich sequences, while their partial involvement in the post-transcriptional regulation of CD154 mRNA stability has been reported. With 96h culture in vitro, the destabilization of CD154 mRNA was demonstrated, resulting in a corresponding decrease and normalization of surface expression on activated SLE T cells. We suggest that the CD154 expression on T cells from SLE patients may be increased and prolonged, with mRNA stabilization being related to a continuous stimulation in vivo.
  • Reseach for the mechanism of over-expression of soluble CD40-ligand and regulating drugs., Ministry of Education, Culture, Sports, Science and Technology, Grants-in-Aid for Scientific Research(基盤研究(C)), Kazunori Kato, Specific aim of this project is to determine the levels of soluble CD40-ligand (sCD154) in the plasma of patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and rheumatoid vasculitis (RV), and to examine the relationship between the levels of sCD154 in plasma and the clinical variables. The levels of sCD154 were quantified in 39 plasma samples from patients with RA, including 9 patients who were also diagnosed with RV, and compared with those of 20 healthy subjects. Sandwich ELISA specific for sCD154 was established and specificity of the ELISA was tested by control ELISA using isotype-matched IgG and preabsorption assay. The titers of IgM and IgG rheumatoid factor (IgM-RF, IgG-RF) for each patient were determined simultaneously, and values of other laboratory variables were also determined. Levels of sCD154 inplasma were higher in patients with RA than in the healthy subjects (p < 0.02). Compared with RA patients without vasculitis, patients with RV had significantly higher levels of sCD154 in their plasma (p < 0.001). Control ELISA and absorption assay of sCD154 indicated that our ELISA system was capable of measuring plasma sCD154 in RA patients. Levels of sCD154 in RA plasma correlated significantly with both of IgM-RF and IgG-RF titers (r = 0.64 and 0.61, respectively, both p < 0.001), The levels of sCD154 decreased after commencement of treatment for vasculitis in cases with RV. In conclusion, we identified the presence of sCD154 in RA plasma, with especially high levels in cases with vasculitis. Correlation between sCD154 and RF titers indicates the CD154-CD40 pathway is likely related to pathogenic RF production.